A combinatorial strategy for treating KRAS-mutant lung cancer - Wikidata - wikimedia - TriplyDB

A combinatorial strategy for treating KRAS-mutant lung cancer

A combinatorial strategy for treating KRAS-mutant lung cancer

http://www.wikidata.org/entity/Q37080881

about

Inhibition of the fibroblast growth factor receptor (FGFR) pathway: the current landscape and barriers to clinical application A Pipeline for Drug Target Identification and Validation BCKDK of BCAA Catabolism Cross-talking With the MAPK Pathway Promotes Tumorigenesis of Colorectal Cancer Tissue-specific tumorigenesis: context matters.Dichotomy of cellular inhibition by small-molecule inhibitors revealed by single-cell analysis.Vemurafenib-resistant BRAF-V600E-mutated melanoma is regressed by MEK-targeting drug trametinib, but not cobimetinib in a patient-derived orthotopic xenograft (PDOX) mouse model Concomitant inhibition of receptor tyrosine kinases and downstream AKT synergistically inhibited growth of KRAS/BRAF mutant colorectal cancer cells.Decomposing Oncogenic Transcriptional Signatures to Generate Maps of Divergent Cellular States.Targeting metabolic reprogramming in KRAS-driven cancers.Combinatorial Screening of Pancreatic Adenocarcinoma Reveals Sensitivity to Drug Combinations Including Bromodomain Inhibitor Plus Neddylation Inhibitor.Measuring Cancer Drug Sensitivity and Resistance in Cultured Cells.Cytokines and metabolic factors regulate tumoricidal T-cell function during cancer immunotherapy.Rho GTPases: Anti- or pro-neoplastic targets?Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients.Defeat mutant KRAS with synthetic lethality.Integrating functional genomics to accelerate mechanistic personalized medicine.Advances and challenges in targeting FGFR signalling in cancer.Pharmacotherapeutic Management of Pancreatic Ductal Adenocarcinoma: Current and Emerging Concepts.Strategies for monitoring and combating resistance to combination kinase inhibitors for cancer therapy.Major Tumor Suppressor and Oncogenic Non-Coding RNAs: Clinical Relevance in Lung Cancer.The EMT spectrum and therapeutic opportunities.Lung cancer samples preserved in liquid medium: One step beyond cytology.Synthetic lethal short hairpin RNA screening reveals that ring finger protein 183 confers resistance to trametinib in colorectal cancer cells.An integrative approach unveils FOSL1 as an oncogene vulnerability in KRAS-driven lung and pancreatic cancer.Clinicopathological, radiographic, and oncogenic features of primary pulmonary enteric adenocarcinoma in comparison with invasive adenocarcinoma in resection specimens.KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancer.High-throughput RNAi screen for essential genes and drug synergistic combinations in colorectal cancer.Molecular subtype specific efficacy of MEK inhibitors in pancreatic cancers Combined MEK and ERK inhibition overcomes therapy-mediated pathway reactivation in RAS mutant tumors.A novel prognostic marker of non-small cell lung cancer: chromosome 9 open reading frame 86 (C9orf86).Understanding and targeting resistance mechanisms in NSCLC.Mutational analysis of KRAS and its clinical implications in cervical cancer patients.In silico-based screen synergistic drug combinations from herb medicines: a case using Cistanche tubulosa.Blocking transferrin receptor inhibits the growth of lung adenocarcinoma cells in vitro.Improving the efficacy-safety balance of polypharmacology in multi-target drug discovery.Synergistic activity and heterogeneous acquired resistance of combined MDM2 and MEK inhibition in KRAS mutant cancers.Cooperative targeting of melanoma heterogeneity with an AXL antibody-drug conjugate and BRAF/MEK inhibitors.Synthetic Lethal Vulnerabilities in KRAS-Mutant Cancers.A Landscape of Therapeutic Cooperativity in KRAS Mutant Cancers Reveals Principles for Controlling Tumor Evolution.Therapeutic strategies and genetic profile comparisons in small cell carcinoma and large cell neuroendocrine carcinoma of the lung using next-generation sequencing.

P2860

Q28079309-DE16FFAB-DDD7-4548-A52A-BC2D82883A6B Q33793854-9092A43E-B994-4B31-8DAB-B1ED81B8D788 Q33817695-F1E82AA4-BE79-48E4-BBAD-A1DA04AD50CC Q36296335-8B3DE7CA-7456-41B3-8416-3F528F642D71 Q37324081-493E51DD-631D-46CF-AEF1-353FA987046E Q37687695-582FADC4-965C-4213-8BE9-1A5D8A6A9993 Q37706287-63552131-23E8-4945-AFFE-0B3A5973F1EA Q38609992-B1146289-D57B-4F0E-91B4-4A2801F25912 Q38710288-AF56A9BA-20C6-434E-A136-DFAD1BA95697 Q38712272-B5EEDB07-B19E-4223-9724-D779FA0784C6 Q38719360-8AF3DBF8-4424-49F3-95EE-7C7470C26752 Q38779877-008578CF-00DB-443B-A244-E9270BFB337F Q38780866-71A65497-9A4D-477D-BD48-18B0824C4DDF Q38798543-209BF9F8-1ED3-44E4-8D75-4426813FC39B Q38837319-8B640EC4-C5A3-4639-A4ED-98072F86B745 Q38904537-FB7AE740-3260-4B0E-A76F-7A41D4CD620D Q39183442-612802A5-D222-42C3-B542-7DF86D31F602 Q39204274-D65968FB-72E1-409D-A7D8-D7E3A3FBF1F5 Q39255218-24B031B6-759B-45AC-9ED9-E8C008B2A30B Q39293814-242A6946-6081-424A-B78F-BC33F827B499 Q39329818-29006953-E481-4D30-943E-09B686185EE5 Q39356534-9E0288F9-7129-4C29-8810-BEB8DDA8AF12 Q40114381-B233245D-CB91-4E32-96F0-A98852231E0D Q40324354-783B6BB4-521F-43CD-952A-02B203061E08 Q41929369-EE6C2100-DB9B-4C21-B83C-1957ED76289B Q41952724-85C84709-8ECA-4BC1-A358-38A4CA288FAD Q42284911-F183E9B7-DCB3-4034-9DFB-A20A29A574A5 Q42366316-A80227B1-8D44-428F-95F2-0FE79D4658AB Q42370777-2ACC129E-07E0-4598-A807-C2D960DC7F03 Q42384615-C1EF06D6-9069-4E76-A12B-779095530697 Q46915997-72CDA6D5-5285-4C08-8804-FEB352DD40DB Q47140117-CA5BC8D5-0F4A-4901-AC41-470571B72B16 Q47165531-DF0966DB-0436-4DEF-8F2F-41F456262FB4 Q47234596-8B3BBE3F-4C4A-43A5-8D68-0871C0149C5D Q47323180-48990290-02EE-486B-A0A1-CFC51CC84DD0 Q47983657-862D125D-8141-4828-8A89-4A5D87E6A373 Q48243258-08106828-22EC-4579-A800-8BA3369A095A Q48611990-D37DCB66-18AB-490E-A692-6C8B83611EF4 Q48711405-58D3435E-C849-4D1E-AE86-49F54B308EBB Q49296261-FAEC1E76-7A52-487C-8C36-4F098E8EF55A

P2860

A combinatorial strategy for treating KRAS-mutant lung cancer

http://www.wikidata.org/entity/Q37080881

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 22 June 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

A combinatorial strategy for treating KRAS-mutant lung cancer

@en

A combinatorial strategy for treating KRAS-mutant lung cancer.

@nl

type

label

A combinatorial strategy for treating KRAS-mutant lung cancer

@en

A combinatorial strategy for treating KRAS-mutant lung cancer.

@nl

prefLabel

A combinatorial strategy for treating KRAS-mutant lung cancer

@en

A combinatorial strategy for treating KRAS-mutant lung cancer.

@nl

P1433

Q37080881-3D5FCA98-826C-4E03-886E-584BD8E6ADA6

P1476

Q37080881-A4A8B048-E00D-43C9-8D2F-74C42DEFFCD0

P2093

Q37080881-067AF857-BDCC-4AF3-BADF-9DA637803A37

Q37080881-0C3874F3-325E-4E13-AB1C-C98571EB03DF

Q37080881-21FBDB6E-FB5A-4D20-B41F-D491DFCBDBAF

Q37080881-5274A52C-942D-4B41-B820-AA91CC8392A5

Q37080881-6B73E0F9-76ED-423A-A0DC-49F3971236B7

Q37080881-9602C669-2A3A-4F2D-80F7-607B1FEE57BF

Q37080881-A2CB243B-EA0A-4676-AFF8-9F4C5B1727CD

Q37080881-A3BAF067-24E8-44A8-9E4A-2CEFCC5C43A7

Q37080881-B8982D4D-E850-447C-A17E-EDAC1B8961A4

Q37080881-DD02CDF0-D899-4160-99BC-DB535FC21F8E

P2860

Q37080881-01B861E5-6E13-4017-9A20-DE4793D41793

Q37080881-03D9978A-A97D-4817-B8F6-8763653E81C1

Q37080881-0A993CB3-EB3A-44D2-8BA7-AA37569461CB

Q37080881-0FABB470-2EF4-4FC4-BCB6-A159087230B3

Q37080881-29374B1F-AE55-4FEB-AA28-20E87DCBF644

Q37080881-2B9D4C98-A873-4A3A-BB1A-F50879964939

Q37080881-2C2A6F32-A0E3-40AE-9DE4-6180EADCBF96

Q37080881-2F941A8B-E113-4446-B6D0-3F9B6738D46F

Q37080881-350713B1-EBA3-46EA-A891-4212E6CE96CD

Q37080881-4389C457-FF33-4235-9B91-24D97AAF1963

P2888

Q37080881-61D0671A-8FE8-4C4C-BD8E-428FFDDCBDEF

P304

Q37080881-2882CB5F-F60E-4E04-8ECF-3DB70BE03F22

P31

Q37080881-2A30EE7F-5C52-47B1-AE17-17039C07AB54

P356

Q37080881-A4B42820-AF4F-49B1-AE72-3D9C4EAE29CA

P407

Q37080881-1CBE45AF-55AE-49C9-9B16-A1D7D7DF3FAA

P433

Q37080881-1AE4F81C-4379-4CEB-AB3E-DFAF89392DBE

P478

Q37080881-BFBF5369-D746-4425-B9A2-4893E3D2030D

P50

Q37080881-0974F590-0603-4F89-A009-2F5D17AEC0B2

P577

Q37080881-D8C25F25-C563-49AE-B8C9-910B67412BCB

P6179

Q37080881-FDEA80A4-C600-4F64-B3F2-BEDAFCAB8566

P698

Q37080881-4AD041FE-5CE3-42CB-B3B3-DBDBEC68F5D4

P932

Q37080881-002CE8AE-2D77-408F-8E9C-378CB106006D

P356

P1433

P1476

A combinatorial strategy for treating KRAS-mutant lung cancer

@en

P2093

Amaia Lujambio

http://www.w3.org/2001/XMLSchema#string

Charles M Rudin

http://www.w3.org/2001/XMLSchema#string

Chi-Chao Chen

http://www.w3.org/2001/XMLSchema#string

Eusebio Manchado

http://www.w3.org/2001/XMLSchema#string

Jeffrey A Engelman

http://www.w3.org/2001/XMLSchema#string

John P Morris

http://www.w3.org/2001/XMLSchema#string

John T Poirier

http://www.w3.org/2001/XMLSchema#string

Justin F Gainor

http://www.w3.org/2001/XMLSchema#string

Neal Rosen

http://www.w3.org/2001/XMLSchema#string

Ramona Wullenkord

http://www.w3.org/2001/XMLSchema#string

P2860

Disruption of CRAF-mediated MEK activation is required for effective MEK inhibition in KRAS mutant tumors

The protein kinase complement of the human genome

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene

Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase

K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions

Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.

Intrinsic resistance to MEK inhibition in KRAS mutant lung and colon cancer through transcriptional induction of ERBB3.

Targeting RAS signalling pathways in cancer therapy

A lipid-anchored Grb2-binding protein that links FGF-receptor activation to the Ras/MAPK signaling pathway

P2888

P304

647-651

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NATURE18600

http://www.w3.org/2001/XMLSchema#string

P407

P433

7609

http://www.w3.org/2001/XMLSchema#string

P478

534

http://www.w3.org/2001/XMLSchema#string

P50

Elisa de Stanchina

P577

2016-06-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1044449046

http://www.w3.org/2001/XMLSchema#string

P698

27338794

http://www.w3.org/2001/XMLSchema#string

P932

4939262

http://www.w3.org/2001/XMLSchema#string